The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

por Gou, Lan-Ying, Li, An-Na, Yang, Jin-Ji, Zhang, Xu-Chao, Su, Jian, Yan, Hong-Hong, Xie, Zhi, Lou, Na-Na, Liu, Si-Yang, Dong, Zhong-Yi, Gao, Hong-Fei, Zhou, Qing, Zhong, Wen-Zhao, Xu, Chong-Rui, Wu, Yi-Long
Publicado 2016

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

por Chen, Rui-Lian, Zhao, Jun, Zhang, Xu-Chao, Lou, Na-Na, Chen, Hua-Jun, Yang, Xue, Su, Jian, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Zhong, Wen-Zhao, Yan, Hong-Hong, Guo, Wei-Bang, Wu, Yi-Long, Yang, Jin-Ji
Publicado 2018

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

por Lou, Na-Na, Zhang, Xu-Chao, Chen, Hua-Jun, Zhou, Qing, Yan, Li-Xu, Xie, Zhi, Su, Jian, Chen, Zhi-Hong, Tu, Hai-Yan, Yan, Hong-Hong, Wang, Zhen, Xu, Chong-Rui, Jiang, Ben-Yuan, Wang, Bin-Chao, Bai, Xiao-Yan, Zhong, Wen-Zhao, Wu, Yi-Long, Yang, Jin-Ji
Publicado 2016